There is no panel matching the key "Alert"
There is no panel matching the key "MicroAlert"

Cancer & Blood Disorders Clinical Trials

Gundersen Health System has about 100 research studies available for cancer patients at any given time.

With support from Gundersen Medical Foundation, the Cancer and Blood Disorders Center offers research studies through participation in regional and national cancer treatment cooperative groups. By sharing clinical research efforts and measuring collective results, treatments are advanced more rapidly than any institution can accomplish alone. Participation in these groups can shorten the time it takes for us to get new, more effective drugs on the market.

Sometimes patients are concerned that if they don't get the experimental therapy, they will only get a placebo. However, in cancer research, the patient will either get the standard treatment or the new experimental drug that has shown signs to be potentially better than the standard treatment. Not everyone will qualify for a cancer research study, but for those who do, it can offer new hope.

Brain/Central Nervous System Cancer

  • Alliance A221101: Armodafinil in Reducing Cancer-Related Fatigue in Patients With Glioblastoma Multiforme
  • Alliance A071102: Temozolomide with or without Veliparib in Treating Patients with Newly Diagnosed Glioblastoma Multiforme (Suspended as of 10/21/2016)
  • Alliance A071401: Phase II Trial of SMO/ AKT/ NF2 Inhibitors in Progressive Meningiomas with SMO/ AKT/ NF2 Mutations
  • ECOG E3F05: Phase III Randomized Study of Radiotherapy With Versus Without Temozolomide in Patients With Symptomatic or Progressive Low-Grade Gliomas(Temporarily Suspended)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NCCTG N0577: Phase III Randomized Study of Radiotherapy Alone Versus Radiotherapy With Concurrent and Adjuvant Temozolomide Versus Temozolomide Alone in Patients With Newly Diagnosed 1p/19q Codeleted Anaplastic Glioma
  • NRG-BN001: Randomized Phase II Trial of Hypofractionated Dose-Escalated Photon IMRT or Proton Beam Therapy Versus Conventional Photon Irradiation with Concomitant and Adjuvant Temozolomide in Patients with Newly Diagnosed Glioblastoma
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Breast Cancer

EARLY STAGE

Adjuvant

  • AFT-05/PrE0109 - PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer (PALLAS)
  • Alliance A011401 - Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL)
  • ECOG E1Z11: Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer (Caucasian/Other races cohort closed to accrual 2/24/2014)
  • NRG-BR003: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
  • NSABP B-51: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
  • SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy
  • WF-97116: A Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil in Chemotherapy Exposed Breast Cancer Survivors with Cognitive Impairment

Neoadjuvant

  • Alliance A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
  • ECOG EA1131 - A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

ADVANCED/METASTATIC

  • ECOG E2112: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Postmenopausal Patients with Hormone Receptor-Positive Advanced Breast Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases. (Closed for patients with peripheral lung metastases, bone metastases, Spinal/paraspinal)
  • NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • SWOG S1416: Phase II Randomized Placebo-Controlled Trial of Cisplatin with or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

Gastrointestinal Cancer

COLORECTAL

  • EPOCH - TS-102: Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic Colorectal Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • SWOG S0820: A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)

HEPATOCELLULAR

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

GASTRIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

ESOPHAGEAL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

PANCREATIC

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • RTOG 0848: Phase III Randomized Study of Adjuvant Gemcitabine Hydrochloride With Versus Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With Versus Without Chemoradiotherapy With Either Capecitabine or Fluorouracil in Patients With Resected Head of Pancreas Adenocarcinoma
  • SWOG S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

CHOLANGIOCARCINOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Genitourinary Cancer

BLADDER

  • S1314: Gene Expression Profiling in Predicting Chemotherapy Response in Patients with Localized, Muscle-Invasive Bladder Cancer
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

PROSTATE

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases (Closed for patients with peripheral lung metastases, bone metastases, Spinal/paraspinal)
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • RTOG 0924: Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
  • SWOG S1602: A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer
  • TRUMPET: A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer in the United States (CRPC)

RENAL CELL

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Gynecological Cancer

CERVICAL

  • GOG 0263: Phase III Randomized Study of Adjuvant Radiation Versus Chemoradiation Therapy in Patients With Intermediate-Risk Stage I-IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • RTOG 0724: Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiotherapy With Versus Without Adjuvant Chemotherapy in Patients With High-Risk Early-Stage Cervical Carcinoma After Radical Hysterectomy

ENDOMETRIAL

  • GOG 0238: Phase II Randomized Study of Pelvic Radiotherapy With Versus Without Cisplatin in Patients With Recurrent Endometrial Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

OVARIAN, PRIMARY PERITONEAL OR FALLOPIAN TUBE

  • GOG 0225: Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • NRG-GY004: A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • NRG-GY005: A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) (SUSPENDED 6/16/2017)

Head and Neck Cancer

  • Alliance A091404 - Enzalutamide in Treating Patients with Androgen Receptor Positive Locally Advanced or Metastatic Salivary Cancers That Cannot Be Removed by Surgery
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • NRG-HN001: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
  • RTOG 1216: Radiation Therapy With Cisplatin, Docetaxel, or Cetuximab After Surgery in Treating Patients With Stage III-IV Squamous Cell Head and Neck Cancer SUSPENDED 02/22/2016

Leukemia

ACUTE LEUKEMIA

ALL

  • ECOG E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

AML

  • ECOG E2906: Phase III Randomized Study of Clofarabine Versus Daunorubicin Hydrochloride and Cytarabine Followed by Decitabine Versus Observation in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (Suspended 02/23/2015)

CHRONIC LEUKEMIA

  • No studies available at this time

Lung Cancer

NON-SMALL CELL

  • Alliance A081105: Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)
  • Alliance A151216: Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (ALCHEMIST Treatment Trial)
  • ECOG E4512: Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)
  • EA5142: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) - A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers(An ALCHEMIST Treatment Trial)
  • MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients with Recurrent Stage IV Squamous Cell Lung Cancer
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-BR001: A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases (Closed for patients with peripheral lung metastases, bone metastases, Spinal/paraspinal)
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • PrECOG PrE0504 - A Phase I/II Study of Glembatumumab Vedotin in Patients with gpNMB-Expressiong Advanced or Metastatic Squamous Cell Carcinoma of the Lung
  • SWOG S1403: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC)(BI 1200.124)

SMALL CELL

  • CALGB 30610: Phase III Randomized Study of Three Different Thoracic Radiotherapy Regimens in Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

MESOTHELIOMA

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Lymphoma

HODGKIN'S

  • CALGB 50801: Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

NON-HODGKIN'S

  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Melanoma

  • ECOG EA6141: Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma (SUSPENDED 6/23/2017)
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases
  • SWOG S1320: A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib and Trametinib in BRAF V066E/K Mutant Melanoma

Multiple Myeloma

  • Alliance A061202: A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy
  • Alliance A061402: Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid Versus Zoledronic Acid After Definite Radiation Therapy
  • ECOG E1A11: Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma
  • MATCH: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors or Lymphomas
  • MERCK MK3475-185: A Phase III Study of Lenalidomide and Low-Dose Dexamethasone with or without Pembrolizumab (MK-3475) in Newly diagnosed and Treatment-Naive Multiple Myeloma (KEYNOTE 185) (SUSPENDED 7/21/2017)
  • SWOG S1211: Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma ACCRUAL SUSPENDED 6/2/2016

Myelodysplastic Syndrome

  • No studies available at this time

Pediatric Oncology

For more information regarding our pediatric trials, please contact:

Nancy Fisher
(608)775-2733
nrfisher@gundersenhealth.org

Dana Barbour
(608)775-0646
dlbarbou@gundersenhealth.org

Prevention/Symptom Management

  • DCP-001: Use of a Clinical Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
  • ECOG E1Z11: Anastrozole in Treating Aromatase Inhibitor Musculoskeletal Symptoms in Female Patients With Stage I-III Breast Cancer (Caucasian/Other races cohort closed to accrual 2/24/2014)
  • GLNE010: Validation of Colon Biomarkers for the Early Detection of Colorectal Adenocarcinoma (Temporarily Closed to Accrual)
  • GOG 0225: Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
  • NRG-CC001: Memantine Hydrochloride and Whole-Brain Radiotherapy with or without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients with Brain Metastases

Sarcoma

  • No trials currently available.

Screenings

  • ECOG-ACRIN EA1141: Comparison of Abbreviated Breast MRI and Digital Breast Tomosynthesis in Breast Cancer Screening in Women with Dense Breasts

If you are interested in getting additional information on a research study, please contact:

Lori Meyer, RN, OCN, CCRC
(608) 775-2579 or (800) 362-9567, ext. 52579
lameyer@gundersenhealth.org

Kathy Frisby, BSN, RN, OCN
(608) 775-6631 or (800) 362-9567, ext. 56631
kafrisby@gundersenhealth.org

Love + Medicine

Every day, Gundersen Health System delivers great medicine plus a little something extra—we call it Love + Medicine.

Share Your Story